Reusing immunotherapy for stomach cancer as second treatment
Part of Cancer, Digestive system clinical trials.
This study looks back at patients with advanced stomach cancer who received immunotherapy again as a second treatment. It aims to understand if giving the same type of immune-boosting drug a second time can help people who already got it as their first therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer of the stomach or where the stomach meets the esophagus.
- You previously received at least 2 cycles of an immunotherapy drug (like a PD-1 or PD-L1 blocker) as your first treatment.
- Your second cancer treatment also includes at least 2 cycles of the same type of immunotherapy drug.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have not had any other cancer in the past 5 years, and your doctors have recorded your tumor response and survival data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This trial tests a new drug combination (ivonescimab plus paclitaxel) as a second treatment for advanced stomach cancer. It's for people whose cancer grew after first-line therapy with a checkpoint inhibitor plus platinum-based chemotherapy.
This trial tests whether giving immunotherapy after surgery can help prevent stomach cancer from coming back. It is for patients whose tumors show certain markers that suggest immunotherapy may work well.
Hear when a new Gastric Cancer, Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.